Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.64 -1.2%	$0.65	$0.51 ▼ $1.80	$62.15M	0.29	579,873 shs	290,904 shs
BLRX BioLineRx	$4.57 +3.2%	$3.98	$2.30 ▼ $35.60	$18.88M	1.29	233,754 shs	31,144 shs
IFRX InflaRx	$0.79 -2.2%	$1.23	$0.71 ▼ $2.82	$54.23M	1.29	288,542 shs	171,795 shs
LUMO Lumos Pharma	$4.34	$4.34	$1.37 ▼ $4.58	$37.54M	0.74	93,069 shs	N/A
MRKR Marker Therapeutics	$1.53 +4.8%	$1.34	$0.95 ▼ $5.99	$16.52M	1.44	79,758 shs	52,512 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	+3.13%	-3.51%	-3.81%	-47.67%
BLRX BioLineRx	0.00%	+4.48%	-18.57%	+49.66%	-80.57%
IFRX InflaRx	0.00%	+1.58%	+0.35%	-20.80%	-53.57%
LUMO Lumos Pharma	0.00%	0.00%	0.00%	0.00%	+87.07%
MRKR Marker Therapeutics	0.00%	+0.69%	-5.82%	+18.70%	-73.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	1.7493 of 5 stars	3.5	0.0	0.0	0.0	1.7	0.8	1.3
BLRX BioLineRx	3.0047 of 5 stars	3.8	3.0	0.0	0.0	4.3	0.0	0.6
IFRX InflaRx	3.0892 of 5 stars	3.5	5.0	0.0	0.0	1.6	1.7	0.6
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	4.2266 of 5 stars	3.8	3.0	0.0	3.9	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	328.88% Upside
BLRX BioLineRx	3.50	Strong Buy	$26.00	468.93% Upside
IFRX InflaRx	3.00	Buy	$6.60	735.44% Upside
LUMO Lumos Pharma	3.00	Buy	$8.63	98.73% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	760.57% Upside

Current Analyst Ratings Breakdown

Latest BLRX, MRKR, LUMO, IFRX, and ASRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/28/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/2/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.49	$0.05 per share	13.22	$1.27 per share	0.50
BLRX BioLineRx	$28.94M	0.67	N/A	N/A	$4.04 per share	1.13
IFRX InflaRx	$180K	294.63	N/A	N/A	$1.13 per share	0.70
LUMO Lumos Pharma	$2.21M	17.02	N/A	N/A	$3.45 per share	1.26
MRKR Marker Therapeutics	$6.59M	2.63	N/A	N/A	$1.73 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.32	N/A	21.37	N/A	-25.72%	-24.87%	-10.87%	8/6/2025 (Estimated)
BLRX BioLineRx	-$9.22M	-$8.80	N/A	N/A	N/A	-15.21%	-23.93%	-6.80%	8/21/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	-33,362.70%	-64.17%	-53.39%	8/6/2025 (Estimated)
LUMO Lumos Pharma	-$34.03M	-$4.29	N/A	N/A	N/A	-1,583.49%	-233.03%	-129.88%	N/A
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	8/13/2025 (Estimated)

Latest BLRX, MRKR, LUMO, IFRX, and ASRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/27/2025	Q1 2025	BLRX BioLineRx	-$0.84	$1.39	+$2.23	$1.39	$7.72 million	$11.75 million
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.36	1.66	1.35
BLRX BioLineRx	0.37	2.27	2.04
IFRX InflaRx	N/A	5.28	4.86
LUMO Lumos Pharma	N/A	2.66	2.66
MRKR Marker Therapeutics	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
BLRX BioLineRx	1.56%
IFRX InflaRx	42.39%
LUMO Lumos Pharma	33.99%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
BLRX BioLineRx	1.10%
IFRX InflaRx	16.30%
LUMO Lumos Pharma	25.40%
MRKR Marker Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	91.95 million	Optionable
BLRX BioLineRx	40	4.26 million	4.22 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
LUMO Lumos Pharma	30	8.65 million	6.45 million	Not Optionable
MRKR Marker Therapeutics	60	11.31 million	9.67 million	Not Optionable

BLRX, MRKR, LUMO, IFRX, and ASRT Headlines

Recent News About These Companies

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17, 2025 | globenewswire.com

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025 | globenewswire.com

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025 | globenewswire.com

Arkansas Historic Preservation Program hosts National Historic Marker Weekend

April 17, 2025 | stuttgartdailyleader.comS

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

April 1, 2025 | globenewswire.com

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

March 31, 2025 | markets.businessinsider.com

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

March 31, 2025 | globenewswire.com

Marker Therapeutics stockholder vote clears warrant issuance

March 28, 2025 | investing.com

Marker Therapeutics initiated with a Buy at Canaccord

March 5, 2025 | markets.businessinsider.com

Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation

March 5, 2025 | msn.com

Marker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | quiverquant.comQ

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | globenewswire.com

MRKR stock touches 52-week low at $1.61 amid market challenges

February 12, 2025 | msn.com

Brookline Capital sets $4 target on Marker Therapeutics stock

February 11, 2025 | msn.com

Marker Therapeutics initiated with a Buy at Brookline

February 11, 2025 | markets.businessinsider.com

MRKR stock touches 52-week low at $1.8 amid market challenges

January 31, 2025 | msn.com

Marker Therapeutics Announces Board Resignation

January 31, 2025 | msn.com

MRKR stock touches 52-week low at $2.4 amid challenging year

January 21, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts

BLRX, MRKR, LUMO, IFRX, and ASRT Company Descriptions

Assertio NASDAQ:ASRT

$0.64 -0.01 (-1.19%)

As of 04:00 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

BioLineRx NASDAQ:BLRX

$4.57 +0.14 (+3.16%)

As of 04:00 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

InflaRx NASDAQ:IFRX

$0.79 -0.02 (-2.20%)

As of 04:00 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Lumos Pharma NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Marker Therapeutics NASDAQ:MRKR

$1.53 +0.07 (+4.79%)

As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time